Lilly Asia Ventures
Bin Li, Ph.D., is a Venture Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, Bin was Head of Research and BD at Fosun Kite, and prior to that, he spent 12 years at AbbVie as Director, Search and Evaluation, JAPAC and Site Head of Abbott/AbbVie R&D Center in Shanghai. Bin had 30 years of pharmaceutical R&D experience in pharma (AbbVie, Roche, Pfizer) and biotech (Anadys, X-ceptor) companies and holds a Ph.D. degree from Penn State University, MS from Iowa State University, and BS from Lanzhou University.
This person is not in the org chart
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.